PA-NORDIC-GROUP-B.V.
Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board (MAB) which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma).
Dr. Donnenfeld joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® canalicular gel. The FDA-cleared hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system.
“Nordic Pharma continues to build a world class group of key opinion leaders with Eric agreeing to lead our esteemed MAB in the U.S. as we prepare to bring LACRIFILL to market. With over 30 years of clinical experience as an internationally recognized expert and pioneer in refractive, cornea and cataract surgery he brings invaluable insights for developing physician led strategies, enhancing the patient experience and phase IV study initiatives,” said Philip Gioia, President of the U.S. team that will launch LACRIFILL under the Nordic Pharma brand. “As one of the leading refractive and cataract surgeons in the United States he shares Nordic Pharma’s commitment to making a sustainable impact on the health of people with dry eye disease.”
"I have been fortunate to work closely with Eric over the last 20 years. He is an outstanding clinician and surgeon with a pulse on new technology," said Jai G. Parekh, MD, MBA, Chief Commercial Officer of Nordic Pharma Eye Care U.S. "Eric is responsible for many of the most successful launches in eye care and our team looks forward to collaborating with him. He will be instrumental in guiding us during LACRIFILL's introduction to eye care providers and patients."
“I’m excited to be part of the LACRIFILL launch as this technology is disruptive and will change the way we practice ophthalmology and optometry,” said Dr. Donnenfeld. “It’s an honor to be working with Nordic Pharma’s leadership and our highly respected Medical Advisory Board to bring this novel dry eye disease therapy to ophthalmologists and optometrists across the U.S. and then around the world.”
In addition to Dr. Donnenfeld’s appointment, Nordic Pharma has proudly accepted an invitation to join the American-European Congress of Ophthalmic Surgery (AECOS) and will have a significant presence at the AECOS Winter Symposium this week. Dr. Vance Thompson will be sharing benefits of LACRIFILL with physicians and leaders in ophthalmology. Select pre-order opportunities will also be discussed. Dr. Thompson will also be presenting the Dry Eye Disease Update session.
About Eric D. Donnenfeld, M.D.
Dr. Donnenfeld is the founding partner of Ophthalmic Consultants of Long Island and Ophthalmic Consultants of Connecticut. He has authored more than 210 papers on the cornea, external disease, cataracts, and refractive surgery, 500 scientific articles, and 50 books and book chapters on a range of subjects pertaining to corneal transplants, cataract care, and laser vision correction.
Dr. Donnenfeld is on the editorial board of nine journals and has participated in over 40 FDA studies. He is one of the first 5 people in the world to perform both laser vision correction and laser cataract surgery. Dr. Donnenfeld is a Fellow of the American Academy of Ophthalmology and has received its Honor Award, Senior Honor Award, Life Achievement Honor Award, and Secretariat Award. He is past President of the American Society of Cataract and Refractive Surgery, President-elect of the International Intraocular Implant Society, and Editor in Chief of EyeWorld. He was named #1 on Newsweek’s America’s Best Eye Doctors list in 2022 and 2021. In addition, Cataract & Refractive Surgery Today recognized Dr. Donnenfeld as one of the Top 50 Most Influential Ophthalmologists in the United States; The Ophthalmologist named Dr. Donnenfeld to their Power List in 2022, 2020 and 2018; and he was also selected as Ophthalmology Management’s 25 Leaders in Innovation.
About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women’s Health. Nordic Pharma has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide. Nordic Pharma is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Amring/Nordic Pharma’s business developments and the implementation of Amring/Nordic Pharma’s strategic initiatives. Because these statements reflect Amring/Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring/Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring/Nordic Pharma, and other factors that could affect Amring/Nordic Pharma’s business and financial performance. Amring/Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226872185/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hero MotoSports Team Rally Secures an Impressive 7th Place Overall Finish at Dakar Rally 202517.1.2025 21:31:00 CET | Press release
The Indian Manufacturer Team’s Second-Best Dakar Performance in Nine Years Hero MotoSports Team Rally, the motorsport team of the world’s largest manufacturer of motorcycles and scooters - Hero MotoCorp, has successfully completed the Dakar Rally 2025, reinforcing its position as a formidable force in the world’s toughest rally. The team completed this year’s rally at overall 7th position, registering its second best Dakar performance in nine years, after it finished 2nd overall at the world’s toughest rally last year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250117472643/en/ Hero MotoSports at Dakar Rally Stage 12 (Photo: Business Wire) The team’s young Chilean rider, Nacho Cornejo, delivered a stellar performance, maintaining top-10 standings throughout the rally and securing an overall 7th place finish. Nacho showcased remarkable grit and determination, demonstrating his consistency across the stages. Since Stage 1,
Qualcomm Announces Quarterly Cash Dividend17.1.2025 15:00:00 CET | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.85 per common share, payable on March 27, 2025, to stockholders of record at the close of business on March 6, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business, QTL, and the vast majority
Jefferies Clients, Shareholders and Employees Contribute $10 Million to Charities Supporting Los Angeles Wildfire Relief17.1.2025 14:00:00 CET | Press release
Jefferies announced today that it will donate $10 million to charities providing aid for first responders and the people and communities impacted by the wildfires across Los Angeles. The donation includes funds from Jefferies, voluntary contributions from its nearly 6,000 worldwide employees, and proceeds from the firm’s January 16 Doing Good Global Trading Day, which set aside 100% of net global trading commissions for charities. Rich Handler, CEO, and Brian Friedman, President of Jefferies, said: “We are so grateful for how the Jefferies network stepped up to support those in need in Los Angeles. These wildfires have inflicted heartbreaking devastation on communities and so many families, and we hope this donation will help deserving charities provide urgently needed relief.” Organization Charity Description Allocation Los Angeles Fire Department Foundation The LAFD is actively seeking funds to equip LAFD members battling wildfires with tools and supplies. $2,000,000 All Hands and He
SLB Announces Fourth-Quarter and Full-Year 2024 Results, Increases Dividend and Initiates $2.3 billion in Accelerated Share Repurchases17.1.2025 12:50:00 CET | Press release
Fourth-quarter revenue of $9.28 billion increased 1% sequentially and 3% year on year Fourth-quarter GAAP EPS of $0.77 decreased 7% sequentially but was flat year on year Fourth-quarter EPS, excluding charges and credits, of $0.92 increased 3% sequentially and 7% year on year Fourth-quarter net income attributable to SLB of $1.10 billion decreased 8% sequentially and 2% year on year Fourth-quarter adjusted EBITDA of $2.38 billion increased 2% sequentially and 5% year on year Fourth-quarter cash flow from operations was $2.39 billion and free cash flow was $1.63 billion Board approved a 3.6% increase in quarterly cash dividend to $0.285 per share Full-year revenue of $36.29 billion increased 10% year on year Full-year GAAP EPS of $3.11 increased 7% year on year Full-year EPS, excluding charges and credits, of $3.41 increased 14% year on year Full-year net income attributable to SLB of $4.46 billion increased 6% year on year Full-year adjusted EBITDA of $9.07 billion increased 12% year o
Perpetual Atomics and QSA Global Sign Collaboration Agreement17.1.2025 11:03:00 CET | Press release
Perpetual Atomics Ltd has partnered with QSA Global, Inc. (USA) to process americium into sealed sources for radioisotope power systems, enabling transformative nuclear technology for future space missions. Perpetual Atomics is excited to announce this collaboration, which will enable the processing of americium into sealed sources for use in radioisotope power systems, including radioisotope heater units (RHUs) and radioisotope thermoelectric generators (RTGs). This partnership is another step toward supporting sustainable and reliable power solutions for some of the most challenging environments in space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107229344/en/ Perpetual Atomics Team gathered at the University of Leicester (Photo: Business Wire) A University of Leicester spinout, Perpetual Atomics brings over 20 years of expertise in space nuclear power systems and exploration, delivering innovative, reliable soluti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom